| Entry |
|
|---|
| Name |
Bromocriptine mesylate (USP);
Bromocriptine mesilate (JP18);
Parlodel (TN) |
|---|
| Product |
|
|---|
| Generic |
|
|---|
| Formula |
C32H40BrN5O5. CH4SO3
|
|---|
| Exact mass |
749.2094
|
|---|
| Mol weight |
750.7002
|
|---|
| Structure |
|
|---|
| Simcomp |
|
|---|
| Class |
Neuropsychiatric agent
DG01472 Dopamine agonist
DG01468 Dopamine D2-receptor agonist
DG01964 Ergot alkaloid
DG01967 Antiparkinson agent
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
Metabolizing enzyme inhibitor
DG02852 CYP3A/CYP3A4 inhibitor
DG01522 CYP3A4 inhibitor
|
|---|
| Remark |
| Therapeutic category: | 1169 |
| Product (DG00452): | D00780<JP/US> |
|
|---|
| Efficacy |
Antiparkinsonian, Dopamine D2 receptor agonist, Prolactin inhibitor |
|---|
| Disease |
|
|---|
| Comment |
Ergot alkaloid derivative
|
|---|
| Target |
|
|---|
| Pathway |
| hsa04080 | Neuroactive ligand-receptor interaction |
|
|---|
| Network |
|
|---|
| Metabolism |
Enzyme: CYP3A4 [HSA: 1576]
|
|---|
| Interaction |
CYP inhibition: CYP3A4 [HSA: 1576]
|
|---|
| Structure map |
| map07213 | Dopamine receptor agonists/antagonists |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
G GENITO URINARY SYSTEM AND SEX HORMONES
G02 OTHER GYNECOLOGICALS
G02C OTHER GYNECOLOGICALS
G02CB Prolactine inhibitors
G02CB01 Bromocriptine
D00780 Bromocriptine mesylate (USP) <JP/US>
N NERVOUS SYSTEM
N04 ANTI-PARKINSON DRUGS
N04B DOPAMINERGIC AGENTS
N04BC Dopamine agonists
N04BC01 Bromocriptine
D00780 Bromocriptine mesylate (USP) <JP/US>
USP drug classification [BR:br08302]
Antiparkinson Agents
Dopamine Agonists
Bromocriptine
D00780 Bromocriptine mesylate (USP)
Blood Glucose Regulators
Antidiabetic Agents
Glucose Control Agents, Other
Bromocriptine
D00780 Bromocriptine mesylate (USP)
Hormonal Agents, Suppressant (Pituitary)
Bromocriptine
D00780 Bromocriptine mesylate (USP)
Therapeutic category of drugs in Japan [BR:br08301]
1 Agents affecting nervous system and sensory organs
11 Agents affecting central nervous system
116 Antiparkinsonian agents
1169 Others
D00780 Bromocriptine mesylate (USP); Bromocriptine mesilate (JP18)
Drug groups [BR:br08330]
Neuropsychiatric agent
DG01472 Dopamine agonist
DG01468 Dopamine D2-receptor agonist
DG00452 Bromocriptine
D00780 Bromocriptine mesylate
DG01964 Ergot alkaloid
DG00452 Bromocriptine
D00780 Bromocriptine mesylate
DG01967 Antiparkinson agent
DG00452 Bromocriptine
D00780 Bromocriptine mesylate
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
DG00452 Bromocriptine
D00780 Bromocriptine mesylate
Metabolizing enzyme inhibitor
DG02852 CYP3A/CYP3A4 inhibitor
DG01522 CYP3A4 inhibitor
DG00452 Bromocriptine
D00780 Bromocriptine mesylate
Drug classes [BR:br08332]
Neuropsychiatric agent
DG01967 Antiparkinson agent
D00780 Bromocriptine mesylate
Target-based classification of drugs [BR:br08310]
G Protein-coupled receptors
Rhodopsin family
Dopamine
DRD2
D00780 Bromocriptine mesylate (USP) <JP/US>
Cytokines and receptors
Cytokines
CSF and other factors
PRL
D00780 Bromocriptine mesylate (USP) <JP/US>
Drugs listed in the Japanese Pharmacopoeia [BR:br08311]
Chemicals
D00780 Bromocriptine mesilate
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D00780
Drug groups [BR:br08330]
Neuropsychiatric agent
DG01472 Dopamine agonist
DG01468 Dopamine D2-receptor agonist
DG00452 Bromocriptine
DG01964 Ergot alkaloid
DG00452 Bromocriptine
DG01967 Antiparkinson agent
DG00452 Bromocriptine
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
DG00452 Bromocriptine
Metabolizing enzyme inhibitor
DG02852 CYP3A/CYP3A4 inhibitor
DG01522 CYP3A4 inhibitor
DG00452 Bromocriptine
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
| KCF data |
ATOM 48
1 N1y N 24.4872 -13.9365
2 C1z C 24.5044 -12.6229
3 C5x C 22.2157 -13.9306
4 C1y C 25.6229 -14.6074
5 C1y C 25.6516 -11.9690
6 O2x O 23.3630 -11.9575
7 O1a O 24.4872 -10.9506
8 C1z C 22.2216 -12.6057
9 O5x O 21.8660 -15.1983
10 C5x C 26.8341 -13.9649
11 C1b C 25.6056 -16.1956
12 N1y N 26.7986 -12.6287
13 C1x C 25.6401 -10.6556
14 N1b N 21.0803 -11.9518
15 C1c C 22.2157 -10.8767
16 O5x O 27.9057 -14.6188
17 C1x C 27.9229 -11.9518
18 C1x C 27.9114 -10.6382
19 C5a C 19.9444 -12.6172
20 C1a C 23.1451 -9.7359
21 C1a C 21.5504 -9.7298
22 C1y C 19.9329 -13.9306
23 O5a O 18.7975 -11.9403
24 C2x C 18.7916 -14.5787
25 C1x C 21.0687 -14.5959
26 C2y C 18.7800 -15.8922
27 N1y N 21.0572 -15.9095
28 C8y C 17.6331 -16.5518
29 C1y C 19.9100 -16.5576
30 C8y C 17.6331 -17.8540
31 C8x C 16.4972 -15.8865
32 C1x C 19.9100 -17.8769
33 C8y C 18.7800 -18.5135
34 C8y C 16.4917 -18.5135
35 C8x C 15.3558 -16.5518
36 C8y C 18.7745 -19.8269
37 N4x N 16.4917 -19.8269
38 C8x C 15.3558 -17.8710
39 X Br 19.9043 -20.4865
40 C1c C 26.8144 -16.9003
41 C1a C 28.0393 -16.2001
42 C1a C 26.8085 -18.2700
43 C1a C 22.2640 -16.6209
44 S4a S 30.0087 -19.4145
45 C1a C 28.6380 -19.4088
46 O1d O 31.3853 -19.4145
47 O1d O 30.0031 -18.0438
48 O1d O 30.0031 -20.7911
BOND 53
1 1 2 1
2 1 3 1
3 1 4 1
4 2 5 1
5 2 6 1
6 2 7 1 #Down
7 3 8 1
8 3 9 2
9 4 10 1
10 4 11 1 #Down
11 5 12 1
12 5 13 1
13 8 14 1
14 8 15 1 #Up
15 10 16 2
16 12 17 1
17 13 18 1
18 14 19 1
19 15 20 1
20 15 21 1
21 22 19 1 #Up
22 19 23 2
23 22 24 1
24 22 25 1
25 24 26 2
26 25 27 1
27 26 28 1
28 26 29 1
29 28 30 1
30 28 31 2
31 29 32 1
32 30 33 1
33 30 34 2
34 31 35 1
35 33 36 2
36 34 37 1
37 34 38 1
38 36 39 1
39 6 8 1
40 10 12 1
41 17 18 1
42 27 29 1
43 32 33 1
44 35 38 2
45 36 37 1
46 11 40 1
47 40 41 1
48 40 42 1
49 27 43 1
50 44 45 1
51 44 46 1
52 44 47 2
53 44 48 2
|
|---|
